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Purpose: EULAR guidelines for the treatment of Knee osteoarthritis
(KOA) state that optimal management requires a combination of non-
pharmacological and pharmacological modalities and that paracetamol
is to be tried ﬁrst. Our aim was to evaluate the predictive factors of the
ﬁrst choice line therapeutic strategy in general practitioners (GP)’ practice
in France and Spain.
Methods: Observational, prospective, multicenter 1-yr cohort study in-
cluding patients 50 yrs, suffering from ACR deﬁned KOA, not treated
within the previous 6 months except for non-pharmacological treatment
and/or self-medication with analgesics or low-dose NSAIDs and for whom
it was planned to initiate a ﬁrst line treatment according to the clinical sta-
tus of the patient and the EULAR recommendations. Statistics. To identify
the main predictive factors, multivariate analyses (logistic regressions)
were performed with 1st choice modalities as dependent variables and
clinical data at baseline as explanatory measures.
Results: 383 GPs (50% in each country) included 1038 patients (69% fe-
males; means±SD: age 68±10 yrs, BMI 28.9±4.8 kg/m2, KOA duration
5.2±6.1 yrs). Since baseline patients’ characteristics in France and Spain
were similar, both populations were pooled. Paracetamol alone was pre-
scribed in 828 patients (440 with/388 without non-pharmacological modal-
ities, mainly diet and/or exercices) and paracetamol plus other drugs
(NSAIDs, SYSADOAs) were prescribed in 210 patients (114 with/96
without non pharmacological modalities).
1. Predictive factors of the association paracetamol + other drugs versus
paracetamol alone are presented in table 1. Global GPs’ assess-
ment, pain at night and effusion were signiﬁcant factors in univariate
(p< 0.05), but not in the multivariate analyses, while sex, age, BMI,
past or present comorbidities, uni/bilateral KOA, recent ﬂare-up of
the pain, patient’s pain and patient’s global assessment were not
signiﬁcant at all.
2. The predictive factors of the association paracetamol + non-
pharmacological treatments versus paracetamol alone are presented
in table 2. Sex (females), bilateral KOA, self-medication, sick leave
were signiﬁcant in univariate, but not in the multivariate analyses.
Conclusions: The predictive factors leading to the associations of non-
pharmacological or other pharmacological modalities to paracetamol in
the ﬁrst GPs’ prescription for treating KOA seem different. Previous
pharmacological treatment and request for specialist advice are good
predictors of ajunction of other pharmaceuticals to paracetamol, while
previous non-pharmacological treatments, obesity, recent ﬂare-up and
pain at night are predictors for the adjunction of non-pharmacological
modalities.
Table 1.
Parameters OR 95%CI
Previous pharmacological self-medication (yes vs no) 1.80 1.26−2.57
Specialist advice requested (yes vs no) 2.09 1.27−3.42
Associated hand OA (yes vs no) 1.69 1.23−2.33
Morning stiffness (no vs yes) 1.64 1.11−2.43
Complementary exams requested (yes vs no) 1.46 1.05−2.04
Table 2.
Parameters OR 95%CI
Previous non-pharmacological treatment (yes vs no) 3.97 2.79−5.65
Obesity (BMI30 kg/m2) vs healthy weight 2.05 1.34−3.12
Pain at night (yes vs no) 1.40 1.04−1.89
Recent ﬂare-up of pain (yes vs no) 1.41 1.02−1.97
Associated back pain (yes vs no) 1.59 1.07−2.36
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Purpose: EULAR guidelines for the treatment of knee osteoarthritis
(KOA) state that optimal management requires a combination of non-
pharmacological (NPT) and pharmacological modalities and that parac-
etamol (APAP) is to be tried ﬁrst. We evaluated the predictive factors
explaining the changes in this strategy over time in General Practitioners
(GP)’ practice in France and Spain.
Methods: Observational, prospective, multicenter 1-yr cohort study in-
cluding patients (pts)  50 yrs, with ACR deﬁned KOA, not treated for
6 months except for NPT and/or self-medication with analgesics or low-
dose NSAIDs and for whom a ﬁrst line treatment was initiated according
to their clinical status and EULAR recommendations. Follow-up visits
were conducted at 3-month intervals. Statistics. To identify main predictive
factors, multivariate analyses were performed with 1st change modalities
as dependent variables and data at baseline and at change visit as
explanatory measures.
Results: 383 GPs (50% in each country) included 1038 pts. Since base-
line pt’s characteristics in France and Spain were similar, both populations
were pooled. At baseline, APAP alone was prescribed in 828 pts (440
with and 388 without NPT – mainly diet and/or exercise) and APAP plus
NSAIDs or SYSADOAs in 210 pts (114 with/96 without NPT). Out of the
899 patients receiving APAP at baseline and completing 1-yr, 667 (74%)
continuously received APAP.
1. Change in pharmacological modalities. Among 1038 pts on APAP at
baseline, 582 (59%) changed therapy during the follow-up, mainly
during the ﬁrst (355 pts) quarter. This change occurred on average
at 152 days (median: 110) as follows: stop of all (31%) or at least
one pharmacological modality (15%), addition of at least one (38%)
or switch from one pharmacological modality to another (16%). Some
parameters increased the risk of change (Table 1).
2. Changes in NPT. Among the 554 pts with NPT at baseline, 410 (74%)
changed during the follow-up, mainly during the ﬁrst (307 pts) quarter.
This change occurred on average at 126 days (median: 97), as follows:
stop of all (43%), or at least one NPT (21%), addition of at least one
(17%) or switch form one NPT to another (19%). Some parameters
increased the risk of change (Table 2) while others decreased this risk:
associated hand OA (OR 0.68; 95%CI: 0.55−0.85), bilateral KOA (vs
unilateral: OR 0.81 [0.66−0.96]), previous NPT (OR 0.65 [0.52−0.82]),
APAP at change visit (OR 0.66 [0.50−0.87]).
Conclusions: Not surprisingly, worsening or improvement of signs/
symptoms at any visit increase the risk of change in pharmacological
as well as NPT modalities. Interestingly, direct (night pain) or indirect
(specialist advice or complementary exams required) signs/symptoms of
disease severity at baseline may predict such changes.
Table 1.
Parameters at baseline OR 95%CI
GP’s global assessment (null/mild vs moderate) 1.40 1.02−1.93
Night pain (yes vs no) 1.32 1.10−1.58
Specialist advice (yes vs no) 1.46 1.10−1.94
Complementary investigations (yes vs no) 1.30 1.07−1.58
Parameters at the change visit
Pt’s global assessment (severe/extreme vs moderate) 1.31 1.03−1.67
Pt’s satisfaction (not at all/a little vs moderate) 1.33 1.06−1.67
Complementary investigations (yes vs no) 1.44 1.11−1.87
Table 2.
Parameters at baseline OR 95%CI
Other pharmacologicals than APAP at baseline (yes vs no) 1.42 1.09−1.85
Parameters at change visit
Night pain (yes vs no) 1.33 1.04−1.70
Morning stiffness (yes vs no) 1.40 1.12−1.75
Complementary investigations (yes vs no) 1.40 1.04−1.89
